期刊文献+

Ru-486、安宫黄体酮、环孢菌素、维拉帕米对非P-g介导的卵巢癌耐顺铂细胞株COC1/DDP耐药性的逆转 被引量:1

Ru-486,Medroxyprogesterone Acetate,Cyclosporin A and Verapamil Reverse the MDR Phenotype of the Human Non-P-glycoprotein-translated Cisplatin Resistance Ovarian Cancer Cell Line COC1/DDP
在线阅读 下载PDF
导出
摘要 目的在同一实验系统中比较Ru-486、MPA、VP、CsA对非P-g介导的卵巢癌耐顺铂细胞株COC1/DDP耐药性的逆转作用并对其作用机制进行探讨,为临床克服耐药提供参考依据。方法采用MTT法从细胞代谢,DNA凝胶电泳从细胞凋亡方面系统观察比较DDP、Ru-486、MPA、VP、CsA 5种药物对卵巢癌多药耐药细胞系COC1/DDP的影响及相互关系,检测上述5种药物与COC1/DDP作用时细胞内GSH-ST和GSH-Px活性的变化,并采用westernblotting以Bcl-2抗体为分子探针对上述5种药物与COC1/DDP作用时细胞内Bcl-2基因的表达进行测定对其逆转机制进行探讨。结果1)Ru-486、CsA、MPA对COC1/DDP有直接抑制作用,其抑制率随浓度增高进行性升高,而VP对COC1/DDP没有直接抑制作用。和DDP联用时,Ru-486、MPA、VP、CsA都能显著增强COC1/DDP对DDP的敏感性,达到一定浓度后,可以完全逆转COC1/DDP对DDP的耐药性。这种逆转是通过抑制细胞代谢、诱导细胞凋亡的结果。2)单纯2.5μg/ml的DDP能使GSH-Px及GST活力上升,除VP外,Ru-486等药物可降低GSH-Px和GST活力,与DDP联用时亦如此。提示,Ru-486、CsA、MPA可以通过抑制GSH转移酶系统阻止对细胞损伤的修复而达到对耐药性的逆转。3)单独的DDP、Ru--486等药物非但对Bcl-2的表达没有抑制作用,反而促进了其表达,以MPA最甚。与DDP联用时,却出现了一个有趣的现象,即可以抑制Bcl-2的表达,Ru-486与DDP联用时Bcl-2的表达几乎完全被阻截。结论:VP、Ru-486、CsA和MPA对卵巢癌多药耐药细胞系COC1/DDP的耐药性有确切逆转作用。其逆转机制可能与降低GSH转移酶系统活性有关。当与DDP联用时可以通过降低Bcl-2蛋白表达来逆转耐药。 Objective Ovarian malignant tumor is one of the three most harmful female genital tumor. For lack of efficient treatment,the five-year-survival-rate have long been lowered at the range of 25%-30%. Multi-drug resistance (MDR)is the major reason that results the patient a bad consequence when chemical therapy was done. To investigation the MDR inhibitor has become a very important mission of the tumor chemical therapy since verapamil was found that could be used as a MDR reverser in 1981.Our study is aim to observe systemically the influence of five drugs(DDP, Ru-486,MPA,Vp,CsA)on the non-P-glycoprotein-translated cisplatin resistance cell lines COC1/DDP and their mutual relationships,and try to investigate the mechanism of the reversion. Methods Using MTT to observe the effect of reversion. Apoptosis DNA gel electrophoresis,GSH-ST and GSH-Px analysis as well as western blotting were used to approach the mechanism of reversion. Results Ru-486,CsA,MPA can repress COC1/DDP directly,their repressive rate is in exact ratio to their concentration. VP has not this direct repressive ability. Combined with DDP,all of Ru-486,CsA, MPA,VP can enhance the susceptibility of DDP,when certain concentration is reached,the resistance of COC1/DDP can be totally reversed. This reversion is caused by the metabolism repression,apoptosis induction and DNA damage of cells. Use 2.5 μg/ml DDP can made GSH-Px and GST more active. Except VP,the other three drugs can reduce the activity of GSH-Px and GST,and the result is the same when combined with DDP. It suggest that Ru-486,CsA,MPA can reverse the MDR through repress the GSH transferase system which can repair the damage of cells. Use single drug, such as DDP,Ru-486 et al,can not repress the expression of Bcl-2,they promote the expression,especially when MPA was singly used. But when the drugs were used combined with DDP,an interest phenomenon appeared,they can reduce the expression of Bcl-2 gene. The expression of Bcl-2 was wholly inhabited when Ru-486 was used with the combination of DDP. Conclusion Ru-486,CsA,MPA and VP all definitely have reverse effect on the MDR of COC1/DDP. The mechanism of the reversion is probably the drugs could repress the GSH transferase system which can repair the damage of cells and reduce the expression of Bcl-2 while the drugs used combined with DDP.
出处 《生物技术通报》 CAS CSCD 2008年第2期172-179,共8页 Biotechnology Bulletin
基金 国家自然科学基金资助项目(30371619)
关键词 卵巢癌 多药耐药 逆转剂 凋亡 谷胱甘肽 Bcl-2 Ovarian cancer MDR Reverser Apoptosis GSH Bcl-2
  • 相关文献

参考文献20

  • 1Tao Zhang, Ming Guan, Hongyan Jin, et al.Gynecologic Oncology, 2005,97 : 501-507.
  • 2康楷,黄林.肿瘤细胞耐药及逆转的研究进展[J].贵阳医学院学报,2002,27(1):42-46. 被引量:5
  • 3Baekelandt MM, Holm R, Nesland JM, et al.Anticancer Res, 2000,20 : 1061-7.
  • 4Claudio JA, Emerman JT.Breast Cancer Research & Treatment, 1996,41 (2): 111-22.
  • 5Dayan G, Jauh JM, Baubichon-Cortay H, et al.Biochemistry, 1997,36(49 ) : 15208-15.
  • 6曹漫明,张积仁,汪森明,胡喜钢,周媛.顺铂诱导的人卵巢癌多药耐药细胞系基因表达谱分析[J].广东医学,2006,27(2):184-186. 被引量:1
  • 7Kim IH, Son HY, Cho SW, Ha CS, Kang BH.Toxicology Letters, 2003,138 ( 3 ) : 185-192.
  • 8Batrakova EV, Li S, Alakhov VY, et al.Pharmaceutical Research, 2003,20( 10 ) : 1581-90.
  • 9Fantappie O, Solazzo M, Lasagna N, et al.Cancer Research, 2007,67 ( 10 ) : 4915-23.
  • 10Garrigos M, Mir LM, Orlowski S.European Journal of Bi-hemistry, 1997,244( 2 ) : 664-73.

二级参考文献15

  • 1刘岳彪,陈亚军,尹勇,杨学军,杨亦静,吴德政.肿瘤中GST活性及GSTπ基因表达的研究[J].癌症,1995,14(1):1-3. 被引量:5
  • 2LUND P,SCHUBERT D,NIKETEGHAD F,et al.Autocrine inhibition of chemotherapy response in human liver tumor cells by insulinlike growth factor-Ⅱ[J].Cancer Lett,2004,206(1):85.
  • 3GOUAZE V,ANDRIEU-ABADIE N,CUVILLIER O,et al.Glutathione peroxidase-1 protects from CD95-induced apoptosis[J].J Biol Chem,2002,277(45):42867.
  • 4ZHONG X,SAFA A R.RNA helicase A in the MEF1 transcription factor complex up-regulates the MDR1 gene in multidrug-resistant cancer cells[J].J Biol Chem,2004,279(17):17134.
  • 5VASE P A.Resistance to chemotherapy in advanced ovarian cancer:mechanisms and current strategies[J].Br J Cancer,2003,89(Suppl3):S23.
  • 6YAMAMOTO K,OKAMOTO A,ISONISHI S,et al.Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance[J].Cancer Lett,2001,168(2):173.
  • 7夏奕明 朱莲珍.血和组织中谷胱甘肽过氧化物酵活力测定方法[J].卫生研究,1987,16(4):29-29.
  • 8Akihiro T, Kaori Shinjo, Kazunori O et al.Flow cytometric method for detection of minimally expressed multidrug resistance P-glyco-protein on normal and acute leukemia cells using biotinylated MRK16 and streptavidin-RED 670 conjugate. Jpn J Cancer Res, 1995,86(2): 607.
  • 9Behrens BC,, Batist G, Ozols RF et al. Serial determination of glutathione levels and glutathione related enzyme activities in human tumor cells in vitro, Biochem Pharmacol, 1986,25(13):2257.
  • 10Shin Ji GT, Kazuhiro Y, Tooru M et al. Augmentstion of transport for cisplatin-glutathione adduct in cisplatin resistant cancer cells. Cancer Res, 1995,55(20): 4297.

共引文献4

同被引文献3

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部